Pyoderma Gangrenosum: A Retrospective Study of Clinical Characteristics, Comorbidities, Response to Treatment and Mortality Related to Prednisone Dose
DOI:
https://doi.org/10.2340/00015555-3776Keywords:
pyoderma gangrenosum, comorbidity, immunosuppressants, prednisone, mortality rateAbstract
Pyoderma gangrenosum is an uncommon ulcerative neutrophilic dermatosis. Clinical presentation, location and associated diseases are diverse. Treatment of pyoderma gangrenosum includes treating the underlying comorbidity supplemented with topical and/or systemic agents. However, treatment is often challenging. The aim of this study was to explore the diversity of pyoderma gangrenosum and its treatments. A total of 64 patients with pyoderma, at the Department of Dermatology, Aarhus University hospital, Denmark, were included in the study. The patients’ records were reviewed over a 6-year period for clinical presentation, associated diseases, treatments and response to treatment, time to mortality after diagnosis and prednisone dose over time. A variety of accompanying comorbidities were found, including a possible association with diabetes. Tumour necrosis α inhibitors were used as third- or fourth-line therapy, but showed the shortest time to remission, and use of prednisone was associated with a higher mortality rate. These findings are discussed in relation to future approaches to treatment of pyoderma gangrenosum.
Downloads
References
Su D, Davis M, Weenig R, Powell F, Perry H. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004; 43: 790-800.
DOI: https://doi.org/10.1111/j.1365-4632.2004.02128.x
Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen J, Wollina U. Diagnostic criteria of ulcerative pyoderma gangrenosum a delphi consensus of international experts. JAMA Dermatol 2018; 154: 461-466.
DOI: https://doi.org/10.1001/jamadermatol.2017.5980
Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53: 273-283.
DOI: https://doi.org/10.1016/j.jaad.2004.10.006
Al Ghazal P, Körber A, Klode J, Dissemond J. Investigation of new co-factors in 49 patients with pyoderma gangrenosum. J Dtsch Dermatol Ges 2012; 10: 251-257.
DOI: https://doi.org/10.1111/j.1610-0387.2011.07734.x
Al Ghazal P, Herberger K, Schaller J, Strölin A, Hoff N, Goerge T, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis 2013; 8: 136.
DOI: https://doi.org/10.1186/1750-1172-8-136
Kolios A, Gübeli A, Meier B, Maul J, Kündig T, Nilsson J. Clinical disease patterns in a regional Swiss cohort of 34 pyoderma gangrenosum patients. Dermatology 2017; 233: 268-276.
DOI: https://doi.org/10.1159/000481432
Miller J, Yentzer B, Clark A, Jorizzo J, Feldman S. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010; 62: 646-654.
DOI: https://doi.org/10.1016/j.jaad.2009.05.030
Jockenhöfer F, Klode J, Kröger K, Roesch A, Al Ghazal P, Dissemond J. Patients with pyoderma gangrenosum - analyses of the German DRG data from 2012. Int Wound J 2016; 13: 951-956.
DOI: https://doi.org/10.1111/iwj.12463
Kridin K, Cohen A, Amber K. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol 2018; 19: 479-487.
DOI: https://doi.org/10.1007/s40257-018-0356-7
Binus A, Qureshi A, Li V, Winterfield L. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011; 165: 1244-1250.
DOI: https://doi.org/10.1111/j.1365-2133.2011.10565.x
Vacas A, Torre A, Bollea-Garlatti M, Warley F, Galimberti R. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients. Int J Dermatol 2017; 56: 386-391.
DOI: https://doi.org/10.1111/ijd.13591
Ruscitti P, Cipriani P, Cantarini L, Liakouli V, Vitale A, Carubbi F. Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. J Med Case Rep 2015; 9: 123.
DOI: https://doi.org/10.1186/s13256-015-0603-y
Braswell S, Kostopoulos T, Ortega-Loayza A. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol 2015; 73: 691-698.
DOI: https://doi.org/10.1016/j.jaad.2015.06.021
Patel D, Locke M, Jarrett P. Pyoderma gangrenosum with pathergy: a potentially significant complication following breast reconstruction. J Plast Reconstr Aesthetic Surg 2017; 70: 884-892.
DOI: https://doi.org/10.1016/j.bjps.2017.03.013
Slocum A. A surgeon's nightmare: Pyoderma gangrenosum with pathergy effect mimicking necrotising fasciitis. BMJ Case Rep 2017; Dec 20.
DOI: https://doi.org/10.1136/bcr-2017-222145
Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: A comprehensive review. Am J Clin Dermatol 2012; 13: 191-211.
DOI: https://doi.org/10.2165/11595240-000000000-00000
Patel F, Fitzmaurice S, Duong C, He Y, Fergus J, Raychaudhuri S. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol 2015; 95: 525-531.
DOI: https://doi.org/10.2340/00015555-2008
Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J 2019; 16: 511-521.
DOI: https://doi.org/10.1111/iwj.13067
Quist S, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol 2017; 15: 34-40.
DOI: https://doi.org/10.1111/ddg.13173
Sagami S, Ueno Y, Tanaka S, Nagai K, Hayashi R, Chayama K. Successful use of adalimumab for treating pyoderma gangrenosum with ulcerative colitis under corticosteroid-tapering conditions. Intern Med 2015; 54: 2167-2172.
DOI: https://doi.org/10.2169/internalmedicine.54.4853
Brooklyn T, Dunnill M, Shetty A, Bowden J, Williams J, Griffiths C. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-509.
DOI: https://doi.org/10.1136/gut.2005.074815
Saag K, Koehnke R, Caldwell J, Brasington R, Burmeister L, Zimmerman B. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-123.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Louise Schøsler, Karsten Fogh, Rikke Bech
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
